Igor Mota Rodrigues de Moura

Mr. Igor Mota Rodrigues de Moura

Universidade de São Paulo, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Journal of Luminescence
Verified
Journal Article
Closed access
Igor Mota Rodrigues de MouraIgor Mota Rodrigues de Moura
Igor Mota Rodrigues de Moura
PFPaulo Euzebio Cabral Filho
Paulo Euzebio Cabral Filho
MSMaria A.B.L. Seabra
Maria A.B.L. Seabra
Goreti PereiraGoreti Pereira
Goreti Pereira
GPGiovannia Araujo de Lima Pereira
Giovannia Araujo de Lima Pereira
BSBeate Santos
Beate Santos

7 October 2024 in JACS Au
Verified
Journal Article
Open access
JCJuliana Calit
Juliana Calit
SPSurendra K. Prajapati
Surendra K. Prajapati
EBErnest D. Benavente
Ernest D. Benavente
JAJessica E. Araújo
Jessica E. Araújo
BDBingbing Deng
Bingbing Deng
DBDaniel Y. Bargieri
Daniel Y. Bargieri
Malaria control and elimination efforts would benefit from the identification and validation of new malaria chemotherapeutics. Recently, a transgenic Plasmodium berghei line was used to perform a series of high-throughput in vitro screens for new antimalarials acting against the parasite sexual stages. The screens identified pyrimidine azepine chemotypes with potent activity. Here, we validate the activity of PyAz90, the most potent pyrimidine azepine chemotype identified, against P. falciparum and P. vivax in the asexual and sexual stages. PyAz90 blocked parasite transmission to the mosquito vector at nanomolar concentrations and inhibited in vitro asexual parasite multiplication with a fast-action profile. Through the generation of P. falciparum PyAz90-resistant parasites and in vitro assays of mitochondrial activity, we identified cytochrome b as a molecular target of PyAz90. This work characterizes a promising chemotype that can be explored for the future development of new antimalarials targeting the Plasmodium cytochrome bc 1 complex.

13 May 2016 in physica status solidi (c)
Verified
Journal Article
Closed access
PDF file
TSThiago G. Silva
Thiago G. Silva
Igor Mota Rodrigues de MouraIgor Mota Rodrigues de Moura
Igor Mota Rodrigues de Moura
PFPaulo Euzebio Cabral Filho
Paulo Euzebio Cabral Filho
MPMaria I. A. Pereira
Maria I. A. Pereira
CFClayton A. Azevedo Filho
Clayton A. Azevedo Filho
BSBeate Santos
Beate Santos

15 April 2025 in ACS Infectious Diseases
Verified
Journal Article
Open access
GMGiovana Rossi Mendes
Giovana Rossi Mendes
ANAnderson L. Noronha
Anderson L. Noronha
Igor Mota Rodrigues de MouraIgor Mota Rodrigues de Moura
Igor Mota Rodrigues de Moura
NMNatália Menezes Moreira
Natália Menezes Moreira
VBVinícius Bonatto
Vinícius Bonatto
RGRafael Victorio Carvalho Guido
Rafael Victorio Carvalho Guido
Malaria is a disease caused by pathogenic protozoa Plasmodium spp., with a significant global impact on human health. Increasing resistance of P. falciparum strains to drugs treating malaria highlights the urgent need for the discovery of new antimalarial candidates. Batzelladines are marine guanidine alkaloids that exhibit potent antiparasitic activity. Herein, results of the parasitological profiling assessment of batzelladines F and L are reported. Both compounds exhibited potent antiplasmodial activity, moderate cytotoxicity, and suitable selectivity indexes. Batzelladines F and L are fast-acting P. falciparum inhibitors, with a pronounced inhibitory activity against resistant strains and laboratory-adapted clinical isolates of P. falciparum. Batzelladines F and L also demonstrated ex vivo activity against clinical isolates of P. falciparum and P. vivax, and batzelladine F showed in vivo antimalarial activity in a P. berghei malaria model. The results reported constitute a robust rationale for the development of guanidine alkaloid derivatives as lead candidates for malaria treatment.

31 March 2021 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
Igor Mota Rodrigues de MouraIgor Mota Rodrigues de Moura
Igor Mota Rodrigues de Moura
ATArisson Tranquilino
Arisson Tranquilino
BSBarbara G. Sátiro
Barbara G. Sátiro
RSRicardo O. Silva
Ricardo O. Silva
DODiogo Oliveira-Silva
Diogo Oliveira-Silva
PMPaulo H. Menezes
Paulo H. Menezes

10 October 2025 in ACS Omega
Verified
Journal Article
Open access
ABAriane F. Bertonha
Ariane F. Bertonha
DWDavid E. Williams
David E. Williams
KNKaren J. Nicacio
Karen J. Nicacio
MAMarcelo R. de Amorim
Marcelo R. de Amorim
SSSydney M. Schoellhorn
Sydney M. Schoellhorn
RBRoberto G. S. Berlinck
Roberto G. S. Berlinck
Peptaibols are modified linear peptides that typically include an acyl fragment connected at the N-terminal moiety, a reduced acid extremity and α-aminoisobutyric acid residues as common features, as well as other structural modifications. Peptaibols very often display potent biological activity, in particular, antimicrobial activity. Trichokonins VI (1) and VIII (2) are large peptaibols composed of 20 amino acids, which were previously only characterized by analysis of MS/MS data. We herein report the first full characterization of trichokonins VI (1) and VIII (2) by analysis of NMR data, along with an analysis by electronic circular dichroism and HRMS/MS data. Also, full genome sequencing and analysis of Trichoderma sp. L2-2 allowed us to identify a peptaibol biosynthesis gene cluster and the proposal for a biosynthetic assembly of trichokonins VI and VIII. Trichokonins VI and VIII also demonstrated antiplasmodial activity at the submicromolar range against Plasmodium falciparum.